December 14, 2010 (New Haven, Connecticut) — Additional research confirms that the doubling of cardiovascular risk associated with the now-discontinued COX-2 inhibitor rofecoxib (Vioxx, Merck) ...
London, UK - An independent meta-analysis of clinical trial data with rofecoxib (Vioxx, Merck & Co) published by the Lancet online November 5, 2004 [ 1] shows that a doubling of the risk of myocardial ...
A comparison of internal company documents, data submitted by the company to the FDA, and published clinical trial results indicates that the risk-benefit profile of rofecoxib in clinical trials ...
Please provide your email address to receive an email when new articles are posted on . In 2001, Steve Nissen, MD, and Eric Topol, MD, both cardiologists at the Cleveland Clinic, co-authored a paper ...
Bethesda, MD (August 30, 2006) – The use of the cyclooxygenase-2 (COX-2) inhibitor rofecoxib (Vioxx®) reduces the risk of colorectal adenomas, according to data being published in Gastroenterology, ...
Laboratory and case-control studies suggest a pivotal role for the cyclooxygenase-2 (COX-2) pathway in colorectal carcinogenesis. The purpose of this study was to test whether the COX-2 inhibitor ...
CONCORD, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals today announced that it will host a key opinion leader (KOL) webinar to discuss the unmet medical need in migraine management and the potential ...
Inhibition of cyclo-oxygenase 2 might slow the progression of colorectal cancer, but might also increase the risk of adverse cardiovascular events. The cyclo-oxygenase 2 inhibitor rofecoxib was ...
Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial In ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tremeau Pharmaceuticals, Inc., a new pharmaceutical company focused on providing non-opioid pain treatments for rare diseases, announced today that the U.S. Food and ...
NEW YORK, June 27 (Praxis Press) Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) but it is unclear whether specific COX-2 inhibitors ...
Clinical studies have failed to show convincing effects of nonsteroidal anti-inflammatory drugs (NSAIDs)—including the selective cyclo-oxygenase 2 (COX2) inhibitor rofecoxib—on the progression of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results